Literature DB >> 14520434

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.

O Krejci, V H J van der Velden, P Bader, H Kreyenberg, N Goulden, J Hancock, M W Schilham, A Lankester, T Révész, T Klingebiel, J J M van Dongen.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14520434     DOI： 10.1038/sj.bmt.1704241

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  22 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

Review 2.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

3.  Therapy of pediatric ALL relapsing after allogeneic transplant: how to make progress with limited patient numbers?

Authors:  M Bierings
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 4.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

5.  Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Authors:  C Eckert; N Hagedorn; L Sramkova; G Mann; R Panzer-Grümayer; C Peters; J-P Bourquin; T Klingebiel; A Borkhardt; G Cario; J Alten; G Escherich; K Astrahantseff; K Seeger; G Henze; A von Stackelberg
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

6.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Authors:  M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

7.  Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India.

Authors:  Divya Subburaj; Lakshman Vaidyanathan; Ramya Uppuluri; Dhaarani Jayaraman; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2017-05-20       Impact factor: 0.900

8.  Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant.

Authors:  Jeong A Park; Thad Ghim; Keun Wook Bae; Kyung Nam Koh; Ho Joon Im; Jong Jin Seo
Journal:  Korean J Hematol       Date:  2010-06-30

Review 9.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

10.  The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yi Zhou; Rebecca Slack; Jeffrey L Jorgensen; Sa A Wang; Gabriela Rondon; Marcos de Lima; Elizabeth Shpall; Uday Popat; Stefan Ciurea; Amin Alousi; Muzaffar Qazilbash; Chitra Hosing; Susan O'Brien; Deborah Thomas; Hagop Kantarjian; L Jeffrey Medeiros; Richard E Champlin; Partow Kebriaei
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.